Unraveling oncogenesis: What makes cancer tick?
Recent discoveries in cancer biology may bring forward an additional collection of tools in physicians’ arsenal of cancer therapeutics. Scientists now know that many cancer-associated mutations affect chromatin regulation and the function of multiprotein transcriptional complexes, which can ultimately lead to cancer development and growth. This knowledge may be used to develop future clinical approaches.
The ASBMB annual meeting is around the corner, and attendees can expect a wide variety of symposia offerings throughout the event. One of the symposia, oncogenic hubs: chromatin regulatory and transcriptional complexes in cancer, will focus on the role of transcriptional dysregulation, histone modification and chromatin regulatory complexes in cancer formation. Cigall Kadoch of Harvard Medical School and Greg Wang of Duke University School of Medicine organized and will lead the session.
Wang, a current Journal of Biological Chemistry editorial board member and 2022 ASBMB Young Investigator Award recipient, said the symposium will focus on cancer but encouraged attendees from all fields to participate in the session.
“These topics can be applied to many other diseases as well,” Wang said.
According to Kadoch, the topics covered at the symposium directly relate to patient care and developing novel therapeutic approaches.
“We’re at a unique moment in time in which the learnings from first-in-class approaches in the clinic are coming back to the bench to inform new questions and propel next-step advances,” Kadoch said. “(We) hope this section of the ASBMB meeting does a good job of covering that.”
Wang added: “(This field) elevates basic science to the translational level to ultimately benefit patients.”
Kadoch and Wang selected a diverse array of speakers who study the role of molecular condensates, extrachromosomal DNA, chromatin regulatory machinery, epigenetics and more in cancer.
“I am particularly excited about the interplay of the speakers within the section and the opportunity for our audiences to take away numerous new approaches to exploring some of the most pressing biological questions relating to oncogenic hubs,” Kadoch said.
Check out the full program schedule to get the most out of #ASBMB25.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreFeatured jobs
from the ASBMB career center
Get the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Mass spec method captures proteins in native membranes
Yale scientists developed a mass spec protocol that keeps proteins in their native environment, detects intact protein complexes and tracks drug binding, offering a clearer view of membrane biology.

Laser-assisted cryoEM method preserves protein structure
University of Wisconsin–Madison researchers devised a method that prevents protein compaction during cryoEM prep, restoring natural structure for mass spec studies. The approach could expand high-resolution imaging to more complex protein systems.

Method sharpens proteome-wide view of structural changes
Researchers developed a method that improves limited proteolysis coupled with mass spectrometry, separating true changes from abundance or splicing effects.

Discoveries made possible by DNA
The discovery of DNA’s double helix revealed how genetic information is stored, copied and expressed. Revisit that breakthrough and traces how it laid the foundation for modern molecular biology, genomics and biotechnology.

Unraveling the language of histones
Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.